Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1139159 | 1.00 | CTSS (0.41) | CTSSTRPV4 | |
| SCHEMBL15653375 | 0.90 | CTSS (0.39) | CTSSTRPV4 | |
| SCHEMBL1139968 | 0.90 | CTSS (0.39) | CTSSTRPV4 | |
| SCHEMBL1139349 | 0.90 | CTSS (0.39) | CTSSTRPV4 | |
| SCHEMBL1139151 | 0.81 | CTSS (0.54) | CTSS | |
| SCHEMBL1139153 | 0.80 | CTSL (0.36) | CTSSTRPV4 | |
| SCHEMBL1139767 | 0.80 | CTSL (0.36) | CTSSTRPV4 | |
| SCHEMBL1139047 | 0.75 | CTSS (0.43) | CTSS | |
| SCHEMBL1139534 | 0.75 | CTSS (0.43) | CTSS | |
| SCHEMBL1139149 | 0.74 | CTSS (0.41) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | claimed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | claimed |
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CTSS 2367/4885TRPV4 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.